Details of Bacterial Vaccine
This bacterial vaccine card gives comprehensive information about each vaccine.
Detailed Information | |
---|---|
ID | 1241 |
Name of the vaccine | H56 |
Microbe | Bacteria |
Disease name | Pulmonary Tuberculosis (TB) |
Name of bacteria | Mycobacterium tuberculosis |
Type of vaccine | Subunit |
Nucleic acid content | DNA |
Age | 18 to 60 years |
Description of the vaccine | H56 fusion protein is formulated with IC31. |
Name of the manufacturer | Aeras |
Name of the manufacturing country | South Africa, Tanzania |
Year of manufacture | 2024 |
Clinical Phase status | Clinical - Phase 2 |
Bacterial strain | Acid-fast Gram-positive bacteria. |
Efficacy | NA |
Vaccine formulation | Suspension for injection |
Dosage | Two doses with a 56 days interval. |
Mechanism of action | NA |
Route of administration | Intramuscular |
Indications | NA |
Export | NA |
Approval | NA |
Adjuvant | IC31 |
Repurposing | NA |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Combination (2 doses) |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NCT03512249 |
Reference | NA |
Other name | NA |
Additional Links | NA |